UBS raised the firm’s price target on ProKidney (PROK) to $8 from $4 and keeps a Buy rating on the shares. Recent data from a Phase 2 trial of rilparencel show stabilization of kidney function in patients with diabetes and advanced chronic kidney disease, the analyst tells investors in a research note. ProKidney expects to meet with the FDA in the near-term to align on eGFR slope as a potential acceptable Phase 3 surrogate endpoint for accelerated approval in advanced CKD, which should give clarity on a potential readout.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PROK:
- ProKidney Enters New $200M Sale Agreement with Jefferies
- ProKidney price target raised to $7 from $6 at Guggenheim
- Nvidia hits $4T market cap, Merck acquires Verona Pharma: Morning Buzz
- Why Is ProKidney Stock (PROK) Up 60% Today?
- ProKidney’s Hold Rating: Balancing Promising Phase 2 Results with Future Uncertainties